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Abstract 
  BACKGROUND:  Glucose-insulin-potassium  (GIK)  may  improve  cardiovascular  performance 
after coronary artery bypass graft surgery (CABG). Our study investigated whether an infusion 
of GIK during elective CABG surgery in type II diabetic patient improved left ventricular per-
formance. 
  METHODS: We measured left ventricular ejection fraction and troponin (Tn), a myofibrillar 
structural protein. In this research, after ethics committee approval, 50 patients with type 2 di-
abetes mellitus (DM) were enrolled into a randomized simple sampling, prospective, double-
blind clinical trial study. In the case group, 500 cc dextrose water 5% plus 80 IU regular insulin 
and 40 mEq KCL were infused at the rate of 30 cc/hr. Patients in control group received 5% dex-
trose solution at the rate of 30cc/hr. Venous blood samples were taken before induction of anes-
thesia,  after  removal  of  the  aortic  clamp  and  before  discharging  from  hospital.  The  Mann-
Whitney-test was used to test for differences in troponin concentration between the groups. 
Fisher’s exact test was used to determine whether there was a difference in the proportion of pa-
tients with a low ejection fraction (<45%) in the case group compared with that in the control 
group. Changes in potassium and glucose concentrations over time within the groups were ex-
amined by ANOVA and paired t-tests. P < 0.05 was regarded as significant level for all tests. 
  RESULTS: In this study, 50 patients with type 2 DM were evaluated in case and control groups. 
The mean age ± SD in the case group was 57.7 ± 9.9 years and in the other group was 61.2 ± 8.4 
years. The groups were well-matched for age, sex and number of bypass grafts. Randomization did 
not give an equal distribution of male and female patients. There wasn’t any significant differ-
ence in ejection fraction between the case and control groups before and after CABG (P > 0.05). 
Troponin concentration in the case group was 3.3 ± 5.0 and in the control group was 3.9 ± 5.1. 
There was no significant difference in Tn between the two groups before and after CABG (P > 
0.05). There was not any significant difference in hospitalization time between the two groups. 
  CONCLUSION: The results suggested that GIK can’t improve left ventricular performance in 
routine CABG surgery. 
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Introduction 
An increasing number of diabetic patients with coro 
nary  artery  disease  have  been  referred  to  surgical 
treatment, considering that the myocardial revascula 
rization surgery is the treatment of choice for the ma 
jority  of  these  patients.1,2  Diabetes  mellitus  may  be 
considered as an independent factor for both mortali 
ty and complications after the myocardial revasculari 
zation  surgery  and  the  motivation  to  reduce  these 
episodes  have  recently  renewed  the  interest  around 
the investigation of glucose insulin potassium (GIK). 
Several experimental studies have evaluated the poss 
ible action mechanisms of GIK3 7, and the treatments 
of  acute  myocardial  infarction  in  diabetic  patients   SM. Seied Hosseini, A. Pourmoghadas, O. Agha Davoodi, M. Amini, M. Mirmohammad Sadeghi, A. Golabchi, B. Hedayatpour, E. Haratian, N. Ghaem Maghami, LKH. Sharegh 
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have  produced  convincing  evidence  of  GIK  bene 
fits.8,9 Some studies have shown a better hemodynam 
ic  performance  using  the  GIK  in  postoperative  di 
abetic  patients  undergone  myocardial  revasculariza 
tion graft surgery .10,11 The use of GIK in myocardial 
revascularization  surgery  has  been  introduced  as  a 
source of metabolic support to the ischemic myocar 
dium since the 1960s,12 nevertheless, remained con 
troversial. During hypoxia, the heart has limited oxid 
ative reserve; and energy rich phosphates are steadily 
depleted.  In  hypoxia,  GIK  may  protect  myocardial 
tissue by maintaining normal carbohydrate and fatty 
acid metabolism and thus, cell function. The effects 
of  GIK  and  its  influence  on  myocyte  metabolism, 
especially during ischemia and reperfusion, are com 
plex. The protective effect of GIK on the functional 
recovery of the heart has been investigated extensive 
ly.13 16  The  different  outcomes  of  GIK  therapy  on 
acute  myocardial  infarction  type  II  diabetic  patient, 
various  protocols  used,  and  different  administered 
doses and various periods evaluated, make it difficult 
to analyze the significant impact of GIK usage. The 
patients  with  diabetes  mellitus  (DM)  could  drive  a 
great benefit from the use of GIK, given the glycemic 
control,  the  decreased  non esterified  fatty  acid  of 
plasma concentrations and the substrate intake to the 
myocardium  at  the  ischemic  trans operative  period 
are  important  factors  in  the  patient's  postoperative 
recovery. Our study investigated whether an infusion 
of GIK during elective coronary artery bypass graft 
(CABG) surgery in type II diabetic patients improved 
left ventricular performance. 
Methods 
The patients were selected with simple sampling in 
this clinical trial study. It was a randomized, prospec 
tive study. Patients with type 2 DM with multivessel 
coronary  artery  disease  admitted  to  the  Shahid 
Chamran hospital in Isfahan, Iran, from January 2007 
to  January  2010  were  eligible  to  participate  in  this 
study.  The  DM  diagnosis  was  made  given  the  pa 
tients' clinical history treated with oral hypoglycemic 
agents or insulin and/or fasting hyperglycemia >126 
mg/dL. After approval of ethics committee, we con 
ducted a double blind prospective randomized clinical 
trial study of 50 patients with type 2 DM who were 
scheduled for elective CABG. Exclusion criteria were 
the  patients  with  chronic  renal  failure  
(with creatinine > 2), acute renal failure (urine output < 
30 ml/hr * 3 times), hyperkalemia (K >5.5 mEq/L) and 
hepatic  failure  with  unknown  causes.  The  patients 
with  other  causes  of  heart  surgery  were  excluded 
from the study. Assessment of ejection fraction was 
part of the routine preoperative evaluation. After get 
ting informed consent, all patients enrolled into study 
were evaluated for ejection fraction by 2D echo, m 
mode  with  vivid  3  echocardiography.  The  patients 
received either 500 cc dextrose water 5% plus 80 IU 
regular insulin and 40 mEq KCL at a rate of 30 cc/hr 
(case  group)  or  an  equivalent  rate  of  5%  dextrose 
(control group), given into a central vein. The infu 
sion started immediately after induction of anesthesia 
and  continued  for  12  hours  after  CABG  surgery. 
Blood glucose was measured hourly with glucometer 
and insulin was given according to the tables 1 and 2.  
 
    Table 1. Schedule to set GIK infusion (case).17,18 
Glycemic index (mg/dl)  Conduct of treatment 
> 270 
 
201 - 270 
126 - 200 
75 - 125 
< 75 
8 IU of human regular insulin in bolus + GIK increase to 6 ml/h 
GIK increase to 3 ml/h 
No Change  
GIK rate decrease to 6 ml/h 
Stop GIK for 15 minutes repeating the blood sugar (BS) measurement  
every 15 minutes until BS reached >125 mg/dl.  
Then, reinitiate GIK infusion with a rate of 6 ml/h. 
 
Table 2. Schedule for administration of insulin subcuta 
neously (control) 
Glycemic index 
(mg/dl)  Conduct of treatment 
80 - 250 
251 - 300 
 
300 - 350 
 
350 - 400 
No insulin 
4  Units of regular human insulin, sub-
cutaneously 
6  Units of regular human insulin, sub-
cutaneously 
8  Units of regular human insulin, sub-
cutaneously 
 
  Potassium was added to achieve a plasma concen 
tration of 4 6 mmol per liter. Peripheral venous blood 
samples were collected for Tn analysis in the case and 
the control groups, 24 hours after CABG. The heart 
surgery  complications  such  as  atrial  fibrillation  and 
the death in the hospitalization period and 3 months 
later were recorded and compared between the two 
groups. Functional class was measured pre  and post  
operatively (3 months later) according to NYHA cri 
teria. The duration from intubation point to the extu 
bation point in ICU called intubation time. The dura 
tion from clamping the ascending aorta to the remov 
al of clamp called clamp time. Pump time was the 
time that patients were on cardiopulmonary pump. 
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Blood sampling and laboratory analysis 
Glucose and potassium plasma concentrations were 
measured  pre CABG,  during  CABG  (trans CABG) 
and  on  the  1st,  2nd,  4th,  6th,  8th,  12th,  18th,  and  24th 
hours, postoperatively. Blood glucoses were obtained 
at each hour until the 6th hour, postoperatively and 
then, at each 2 hours until the 24th hour. Blood sam 
ples were taken into tubes without anticoagulant and 
centrifuged at 2500 g for 20 min. The serum obtained 
was then stored at –70°C until analysis. Quantitative 
Tn analysis was performed using the Bayer Immuno 
assay (Bayer, Leverkusen, Germany), a heterogeneous 
sandwich  magnetic  separation  system  using  mouse 
monoclonal  and  goat  polyclonal  anti Tn  antibodies. 
The randomization was blinded to patients, surgeons, 
and cardiologists, who were directly involved in the 
accomplishment of the protocol and in the measure 
ments, such as clinical, laboratory, and hemodynamic 
data.  The  participants  were  randomized  into  either 
the intervention or control groups. Only the anesthe 
siologist  had  access  to  the  group  information  to 
which the patients was randomized. 
 
Statistical analysis 
A power analysis showed that 25 patients in the case 
and control groups were required to detect a mean 
difference of 0.9 (SD 0.8)  g per liter in Tn concentra 
tion between the two groups at any time point with a 
power of 90% and a P value of 0.05. Non parametric 
statistical tests were therefore used for (Tn) analysis. 
The Mann Whitney test was used to test the differ 
ences in Tn concentration between the two groups at 
each time point. Changes in Tn concentration over 
time  within  the  groups  were  assessed  by  Friedman 
analysis  of  variance  (ANOVA)  and  the  Wilcoxon 
signed ranks test. Fisher’s exact test was used to de 
termine whether there was a significant difference in 
the proportion of patients with a low ejection fraction 
(< 45%) in the case group compared with that in the 
control  group.  Other  categorical  data,  including 
hypertension,  hypercholesterolemia,  preoperative 
myocardial infarction and gender ratio) were also as 
sessed  with  Fisher’s  exact  test.  The  Mann Whitney 
test was used to determine whether Tn concentrations 
were greater in patients with low ejection fractions. 
The  relationship  between  cross clamp  time  and  Tn 
concentration was evaluated by Spearman correlation 
analysis. Patient age, CABG time, aortic cross clamp 
time and blood glucose and blood potassium concen 
trations were normally distributed and were assessed 
with parametric statistical tests. Differences in these 
variables between the case and control groups were 
assessed with t test. Changes in potassium and glu 
cose concentrations over time within the groups were 
examined by ANOVA and paired t tests. P < 0.05 
was regarded as significant level for all tests.  
Results 
The groups were well matched for age and number of 
bypass grafts (Table 3). One patient in group 1 (the 
case group) and two patients in group 2 (the control 
group) had four grafts, and four ones in group 1 and 
11 patients in group 2 received two grafts. All other 
patients had three coronary artery grafts with at least 
one internal mammary artery graft. 
  Randomization did not give an equal distribution of 
male and female patients. Mean ejection fraction before 
surgery in the case and control groups were 50.6% ± 8.1 
and 49.5% ± 12.4, respectively (Table 3). Mean ejection 
fraction before discharge in the case and control groups 
were 44.1 ±6.8 and 46.3 ± 14.9, respectively. There was 
not a significant difference in the mean ejection fraction 
between  the  two  groups  before  and  after  CABG  
(P > 0.05, Table 4). There were not significant changes 
in ejection fraction (EF1 EF2) in the case and control 
groups after CABG (P > 0.05). 
 
Table 3. Patients’ characteristics. Values are presented as mean (SD). 
  Case (GIK group )  Control (Non-GIK group)  P-value 
Age (years)  57.7 (9.9)  61.2 (8.4)  0.18 
Gender ratio (M:F) 
Body mass Index (BMI) 
9:16 
28.7 (5.0) 
14:6 
28.0 (4.7) 
0.04 
0.62 
Pump time (min)  99.0 (23.7)  99 (27.1)  0.6 
clamp time (min)  59.5 (15.0)  61.4 (17.0)  0.68 
Systolic BP  133.8 (18.3)  126.5 (24.1)  0.23 
Cholesterol  190.2 (55.1)  190.9 (44.0)  0.96 
Diabetes duration (years)  5.1 (5.2)  7.4 (6.2)  0.19 
Ejection fraction 
Intubation Time (minutes) 
50.6 (8.1) 
662.2 (208) 
49.5 (12.4) 
734.6 (287.5) 
0.7 
0.32 
Death (in-hospital)  0  1  0.49 
 
  Before  operation,  all  patients  were  on  beta 
blockers  and  aspirin;  the  latter  was stopped  5  days 
before surgery. A large number were also taking cho 
lesterol lowering medications  (statins)  and  angioten 
sin converting enzyme inhibitors. 
 
 
 
Table 4. Mean ejection fraction in both groups before and 
after CABG. Values are presented as mean (SD). 
  Case group  Control 
group  P-value 
EF before 
CABG 
50.6 (8.1)  49.5 (12.4)  0.7 
EF after 
CABG 
44.1 (6.8)  46.3 (14.9)  0.5 
EF1 - EF2  -6.52 (6.9)  -4.13 (6.5)  0.2   SM. Seied Hosseini, A. Pourmoghadas, O. Agha Davoodi, M. Amini, M. Mirmohammad Sadeghi, A. Golabchi, B. Hedayatpour, E. Haratian, N. Ghaem Maghami, LKH. Sharegh 
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Tn concentration 
Mean  Tn  concentrations  in  the  case  and  control 
groups  were  3.3  ±  5.0  and  3.9  ±  5.1,  respectively. 
There was not a significant difference in Tn concen 
trations  between  the  two  groups  after  CABG  
(P > 0.05). 
 
Hospitalization  
The mean hospitalization periods in the case and con 
trol groups were 7.4 ± 8.7 and 7.5 ± 8.8 days, respec 
tively. There was not a significant difference in hospi 
talization periods between the two groups (P = 0.8). 
(Table 5) 
 
Table 5. Mean hospitalization periods in both groups. Val 
ues are presented as mean (SD) 
  Case 
group 
Control 
group  P-value 
Hospitalization  7.4 (8.7) 
days 
7.5 (8.8) 
days  0.8 
 
Functional Class (FC)’ 
Two patient in the case group and no patient in the 
control group had poor FC (class IV), 13 in the case 
group and 9 patients in the control group had fair FC 
(class III), and 9 in the case group and 12 patients in 
the other group had good FC (class II). All other pa 
tients had excellent FC (class I) before CABG (Table 7). 
 
Table 7. Functional class classification in both groups be 
fore CABG. 
Functional Class  Case group  Control group 
excellent(Ι) 
good(ΙΙ) 
fair(ΙΙΙ) 
 
Poor (ΙV) 
1 
9 
13 
2 
3 
12 
9 
0 
 
There  were  significant  changes  in  FC  (FC2 FC1) 
within the case and control groups after and before 
CABG (P = 0.001, Tables 7 and 8). 
  There weren’t any significant changes in atrial fi 
brillation between the case and control groups after 
CABG (P = 0.28, Table 9). 
 
Table 6. Mean potassium and BS levels before, during and after the CABG in both groups.  
Values are presented as mean (SD) 
  Case group  Control group  P-value 
Potassium (before)  4.40 (0.5) meg/L  4.44 (0.48) meg/L  0.7 
Potassium (during)  4.16 (0.4) meg/L  4.42 (0.49) meg/L  0.03 
Potassium (after)  4.15 (0.6) meg/L  4.18 (0.42) meg/L  0.8 
BS (before)  220.6 (105.4) meg/L  188.7 (72.2) meg/L  0.2 
BS(during)  206.0 (47.4) meg/L  244.7 (73.2) meg/L  0.03 
BS (after)  180.0 (56.1) meg/L  187.8 (58.5) meg/L  0.6 
 
Table 8. Functional class classification in both groups 3 
months after CABG. 
Functional Class  Case 
group 
Control 
group 
excellent(Ι)good(ΙΙ)Flair 
(ΙΙΙ) 
Poor(ΙV) 
 
21 
3 
1 
0 
17 
7 
 
0 
 
Table 9. Atrial fibrillation (AF) in both groups after 
CABG. 
AF  Case group  Control group  P-Value 
Yes  1 (4%)  3 (12.5%)  0.28 
 
Discussion 
Perioperative myocardial infarction is a clinically re 
cognizable form of myocardial damage and has a side 
effect.17 The infusion of GIK solutions as a metabolic 
support to myocardium in the perioperative period of 
myocardial  revascularization  surgery  has  been  rec 
ommended many years ago, but there is no consensus 
regarding its benefits. Interest has also grown around 
the potential usage of GIK infusions due to the in 
creasing  number  of  diabetic  patients  submitted  to 
surgical treatment and the search for better outcomes. 
The GIK effects in experimental studies have shown 
its capacity to preserve the contractile function after 
an ischemic period and consequently, a better hemo 
dynamic performance of the heart is expected.3 7 In 
this research, we studied whether an infusion of GIK 
during elective CABG surgery in type II diabetic pa 
tients  improved  left  ventricular  performance.  To 
quantify the amount of left ventricular performance 
perioperatively,  we  used  Tn  concentration,  ejection 
fraction and functional class.17 The maximum value of 
Tn can be used to quantify the extent of myocardial 
cell death.17,18 Tn is accepted as a marker of perioper 
ative risk stratification in cardiac risk patients under 
going  non cardiac  surgery19  and  in  patients  under 
going CABG, because its concentration is related to 
the  amount  of  irreversible  cell  injury.  Higher  peri 
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postoperative  complications.20  Ejection  fraction  and 
functional class are related to the amount of individu 
al capacity and functional capacity of the heart. It has 
also been used to indicate underlying cardiac injury in 
intensive care patients21,22 and to examine the benefits 
of different solutions and temperatures of cardiople 
gia.23 The heart is most likely to sustain ischemic in 
jury when the aortic cross clamp is applied. This is 
supported  by  our  finding  of  a  correlation  between 
cross clamp time and peak Tn concentration. 
In this study, despite the theoretical protective effects 
of GIK listed above and the increase in functional 
class,  no  cardioprotective  effect  of  GIK  was  ob 
served.  We  did  not  find  a  significant  difference  in 
ejection fraction between the two groups. Maybe, our 
results supported the findings of other studies,13 but 
there was no difference between GIK and non GIK 
treated patients. Before concluding that GIK confers 
no  protective  effect  on  the  myocardium  during 
CABG surgery, other possible reasons for our nega 
tive findings should be considered. We used a high 
dose of GIK, as recommended in other studies,24,25 
but  continued  this  only  12  hours  after  surgery.  It 
might be of more benefit if started before surgery and 
continued for 24 48 hours after surgery, as suggested 
by other studies. Some researchers examined the ef 
fect  of  GIK  on  complications  of  mitral  valve  re 
placement  and  demonstrated  increased  myocardial 
glycogen content after an infusion of GIK, 12 hours 
before  the  operation.26  This  reduced  complications 
such  as  hypothermia  and  arrhythmia  after  surgery. 
Lazar  and  colleagues27  found  better  cardiac  perfor 
mance and faster recovery from urgent CABG in pa 
tients with unstable angina given GIK infusion for 12 
hours after operation. These patients had greater car 
diac output, a significantly lower incidence of atrial 
fibrillation (13.3 vs. 53.3%, P = 0.02) and a shorter 
stay in intensive care. GIK might be beneficial in pa 
tients with decreased cardiac reserve, poor left ventri 
cular  function  and/or  cardiogenic  shock.  Patients 
with a high risk of death may be more likely to benefit 
from  metabolic  therapy.28  Patients  with  insulin 
dependent  diabetes  might  benefit  particularly  from 
GIK, as shown in the DIGAMI study for patients 
with myocardial infarction.29 A recent study by Lazar 
and colleagues found better cardiac performance and 
faster recovery after CABG in a group of 40 diabetic 
patients.30 Postoperative GIK infusion for 48 hours 
was of benefit in patients with refractory cardiac fail 
ure  after  hypothermic  cardiac  arrest  for  CABG.31 
Other authors have been using cardiac index (CI) to 
evaluate the benefits from GIK in myocardial revas 
cularization surgery. A randomized clinical trial pub 
lished in 2000 compared the diabetic patients under 
gone myocardial revascularization surgery using GIK 
(n = 20) or conventional treatment with insulin sub 
cutaneously (n = 20). CI has been shown to increase 
in the intervention group (CI at the 18th hour post 
operative: 2.88 ± 0.50 vs. 2.2 ± 0.39 L/min/m2 in the 
case and control groups, respectively, 95% CI 0.38 
0.97, P < 0.0001).10 Szabó et al11 have studied the di 
abetic patient undergone to myocardial revasculariza 
tion surgery and randomized to the case group with 
high doses of insulin (n = 10) or conventional treat 
ment (n = 10). In the case group there was a signifi 
cant  increase  in  the  CI  (2.3  ±  0.1  vs.  2.9  ±  0.2 
L/min/m2, P = 0.017). An essay published in 2000 
evaluated 45 patients undergone to myocardial revas 
cularization  surgery  without  cardiopulmonary  pump 
and randomized to GIK or saline solution. It was not 
found  any  difference  between  the  groups  regarding 
CI  and  SvO2  (mixed  venous  oxygen  saturation)  as 
well as in the enzymatic variables CPK MB and tro 
ponin I.12 The Insulin Cardioplegia Trial13 evaluated 
the use of 10 IU insulin fortified cardioplegia vs. pla 
cebo in high risk patients undergone myocardial re 
vascularization surgery due to unstable angina. A total 
of 1127 patients were randomized. There was no sig 
nificant  difference  regarding  mortality  rate  and  the 
event  of  enzymatic  infarction  and/or  low  cardiac 
output  syndrome.  This  study  was  criticized  by  not 
considering some existing evidences, such as low in 
sulin dose administered in a single moment and not 
maintained the intervention in the postoperative pe 
riod.32 A meta analysis published in 2004, which in 
cluded 11 studies evaluating the GIK administered in 
the  CABG  postoperatively  or  in  the  valve  replace 
ment relating to 468 patients, estimated an 11.4% in 
crement in the CI of patients who received GIK infu 
sion  with  a  decrease  in  the  atrial  fibrillation  in  the 
postoperative period. 
Limitations  
It is possible that our study was too small and the 
groups were too poorly matched to reveal the benefit 
of GIK. The different proportions of male and fe 
male patients in the case and control groups are un 
likely to have influenced the results, but this possibili 
ty cannot be excluded. The possible influence of the 
ejection  fraction  was  analyzed  retrospectively.  The 
importance of the ejection fraction as a confounding 
factor is uncertain as there was no significant differ 
ence in Tn concentration at any time point between 
patients with low and those with normal ejection frac 
tions. A problem with high glucose infusion is hyper 
glycemia  during  CABG,  which  could  damage  the 
brain.  Hyperglycemia  may  increase  ischemic  brain 
injury. A confounding factor is that high glucose con 
centrations may indicate severe head injury, as hyper   SM. Seied Hosseini, A. Pourmoghadas, O. Agha Davoodi, M. Amini, M. Mirmohammad Sadeghi, A. Golabchi, B. Hedayatpour, E. Haratian, N. Ghaem Maghami, LKH. Sharegh 
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glycemia is a general stress response.29 However, the 
blood  glucose  concentration  should  be  maintained 
within the normal range. Measuring glucose and po 
tassium concentrations regularly is necessary. 
Conclusion 
We did not find that the use of GIK infusion during 
surgery to be useful in myocardial cell damage and 
ejection fraction associated with cardiac surgery and 
CABG. So, routine GIK infusions cannot be recom 
mended  until  further  studies  to  be  performed  that 
demonstrate the value of this practice and determine 
which patients are most likely to benefit. 
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